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Background: There are very few drugs that prevent the relapse of Plasmodium vivax malaria in man. Tinidazole is a
5-nitroimidazole approved in the USA for the treatment of indications including amoebiasis and giardiasis. In the
non-human primate relapsing Plasmodium cynomolgi/macaque malaria model, tinidazole cured one of six
macaques studied with an apparent mild delay to relapse in the other five of 14–28 days compared to 11–12 days
in controls. One study has demonstrated activity against P. vivax in man. Presented here are the results of a pilot
phase II, randomized, open-label study conducted along the Thai-Myanmar border designed to evaluate the
efficacy of tinidazole to prevent relapse of P. vivax when administered with chloroquine.
Methods: This study utilized a modified triangular test sequential analysis which allows repeated statistical
evaluation during the course of enrolment while maintaining a specified power and type 1 error and minimizing
recruitment of subjects. Enrolment was to be halted when a pre-specified success/failure ratio was surpassed. The
study was designed to have a 5% type 1 error and 90% power to show whether tinidazole would produce a
relapse rate of less than 20% or greater than 45% through Day 63 of weekly follow-up after initiation of treatment
and initial parasite clearance with 3 days of an oral weight based dosing of chloroquine and five days of 2 grams/
day of tinidazole.
Results: All subjects cleared their parasitaemia by Day 3. Six of the first seven subjects treated with tinidazole
relapsed prior to Day 63 (average Day 48.3 (range 42–56)). This exceeded the upper boundary of the triangular test
and enrolment to receive tinidazole was halted. A concurrent cohort of five subjects definitively treated with
standard doses of primaquine and chloroquine (historically 100% effective) showed no episodes of recurrent
P. vivax parasitaemia during the 63-day protocol specified follow-up period.
Conclusions: Tinidazole is ineffective in preventing relapse of P. vivax at the dose used. The macaque relapsing
model appeared to correctly predict outcome in humans. Use of the modified triangular test allowed minimal
enrolment and limited unnecessary exposure to the study drug and reduced costs. This adds weight to the ethical
and economic advantages of this study design to evaluate similarly situated drugs.
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Plasmodium vivax accounts for 40% of malaria and is
one of the forms of relapsing malaria due to a persistent
liver stage of the disease in the form of hypnozoites.
There is presently only one approved treatment (prima-
quine 15-30 mg base/d for 14 days) that adequately
eliminates the persistent liver stage of P. vivax, achieving
what is referred to as “radical cure” when used in com-
bination with a blood-stage anti-malarial agent. Prima-
quine and other members of its 8-aminoquinoline class
cause dose-dependent oxidative haemolysis, particularly
in G6PD (glucose-6-phosphate-dehydrogenase) deficient
individuals and requires 14 day dosing leading to prob-
lems with compliance [1-4]. Therefore, the use of prima-
quine requires medical supervision and pre-treatment
testing for G6PD deficiency, especially in areas where
severe deficient phenotypes are known to occur, thus
markedly limiting the utility of primaquine for use in
large scale malaria control and elimination programmes.
It is important to discover new drugs with an acceptable
safety and tolerability profile, with a shorter course of
treatment that can eliminate the persistent liver stage of
P. vivax, thus improving compliance, and which can be
given without medical supervision, and do not require
any pre-treatment screening test. Currently, means of
studying the efficacy of drugs against relapsing malaria
hypnozoites is limited. While it is possible to study drug
efficacy against primate relapsing forms of malaria, there
is no equivalent animal model available for P. vivax.
While the P. cynomolgi primate model has a well dem-
onstrated predictive value against P. vivax in humans
[5], ultimately results from any P. cynomolgi trial and its
applicability to human P. vivax infection can only be de-
finitively assessed with a human trial.
Because of the uncertain applicability of animal
models to human P. vivax, candidate drugs for vivax
malaria may lack convincing evidence sufficient to justify
an intensive trial that would divert resources from
higher yield efforts and that would possibly expose an
unacceptable number of subjects to a failing regimen if
executed using a traditional study design. This study
uses a sequential analysis method known as a modified
triangular test in order to limit enrolment and exposure
to the study product. This method has been used suc-
cessfully with increasing frequency, including in a study
of azithromycin against P. vivax [6-8].
The Military Infectious Diseases Research Program
(MIDRP) has established development of new drugs as
an objective. The ideal drug to prevent relapse would re-
quire a short course of treatment (five days or less), have
an excellent safety profile, be non-haemolytic, have an
accelerated path to formal approval and be widely avail-
able. In the alternative, a secondary, but still valuable
drug would potentiate the effect of primaquine andallow for a lowering of its dose or shortening of its
course thereby reducing haemolytic potential and in-
creasing compliance. Tinidazole is a widely available ap-
proved 5-nitroimidazole drug used in the treatment of
amoebiasis and giardiasis, that lacks significant P450 en-
zyme inhibition and has a proven safety profile [9,10]. In
vitro testing with Plasmodium falciparum and mouse
testing with Plasmodium berghei revealed no apparent
blood stage activity and no or unacceptably slow blood
stage activity with Plasmodium cynomolgi (unpublished
observations Bennett K, 2007). Testing in a causal
prophylaxis chick model with Plasmodium gallinaceum
demonstrated increased survival from 4 days in control
animals to 9.5 days in chicks treated with tinidazole
(Walter Reed Army Institute of Research Chemical In-
formation System Database 2008). Testing with ‘Rhesus’
macaques (Macaca mulatta) using a relapsing strain of
P. cynomolgi, one of six monkeys was cured of liver stage
infection in an arm with 7 daily 150 mg doses of
tinidazole coupled with chloroquine to eliminate the
blood stage of the infection, with the other five monkeys
demonstrating a mild apparent delay to relapse [11].
Relapse in the macaque model was particularly long
(30 and 68 days in two monkeys) versus controls (12 and
16 days in two monkeys), when dosed with chloroquine
for blood stage treatment and a sub-therapeutic dose of
primaquine. One open label human study in 30 subjects
given 2 gms of tinidazole monotherapy once followed by
weekly doses of 500 mgs for 10–12 months cleared all
subjects of blood stage infection within 96 hours with
no recurrences of P. vivax [12]. However, this report of
tinidazole efficacy has significant limitations to include
no control arm, conduct of the study in India where the
strain of P. vivax reportedly has a low relapse frequency
of about 10-20% [13], and with subjects receiving on-
going prophylactic dosing for 10–12 months with the
study product tinidazole at 500 mg given weekly [12].
Overall previous studies suggested some liver stage ac-
tivity in animals and man and possible potentiation of
primaquine. However, the evidence was not sufficient to
justify a full Phase II standard clinical trial on both sci-
entific and ethical grounds. A clinical trial design was
sought to further investigate tinidazole efficacy in
preventing relapse of P. vivax that would limit enrol-




Subjects were otherwise healthy adults, ethnic Karen/
Burmese, non-pregnant, G6PD normal with .P. vivax
infection. All were histidine-rich protein 2 (HRP-2)
negative, reducing the likelihood of P. falciparum co-
infection. Subjects were males and females who resided
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Burmese border. Plasmodium vivax in this region is gen-
erally chloroquine sensitive with a usual mean time to
recurrence of 21 to 63 days if treated with chloroquine
alone, which is the standard of care [14-17]. Primaquine
for radical cure is not routinely used for persons living
in this endemic area, due to toxicity risks and because
re-infection is a continuous risk. Subjects were excluded
if presenting with mixed malarial infection, anaemia or
if there was any concomitant use of metronidazole,
mebendazole or albendazole or use of any drug with
known anti-malarial properties within the preceding four
weeks prior to presentation.
Study design
This was a randomized, open-label, unblinded study ap-
proved by the Walter Reed Army Institute of Research
and the Faculty of Tropical Medicine Mahidol University
institutional review boards conducted in accordance
with International Conference on Harmonisation and
Good Clinical Practice guidelines and applicable Depart-
ment of Defense regulations. Written consent was
obtained from all subjects in their native language. The
study was conducted at the Shoklo Malaria Research
Unit (Mae Kon Kin Clinic), Mae Sot, Thailand. Subjects
were randomized to either a treatment arm with the po-
tential of up to 60 subjects to receive 2 gms of tinidazole
by mouth per day for 5 days coupled with oral chloro-
quine at 25 mg/kg/day for five days or a positive com-
parator arm of up to 24 subjects to receive primaquine
by mouth 30 mg base per day for 14 days coupled with
chloroquine at 25 mg/kg/day for five days. The treat-
ment arm dose combination and regimen was chosen as
it is already an approved treatment regimen for
extraintestinal amoebiasis, and represented the antici-
pated maximal dose for anti-malarial administration.
The positive comparator arm was added to confirm
chloroquine susceptibility (expected 100% cure rate) and
to obtain an estimate of the rate of P. vivax re-infection
in this study population during the study period.
Randomization was done at a 2:1 ratio between the
treatment and active comparator arms. Malaria blood
smears were done daily until blood stage clearance was
achieved for two consecutive days and then weekly
follow- up smears were performed until Day 90 with a
statistical cut-off of follow-up at Day 63. Primary end-
points were recurrence or lack of recurrence with
P. vivax through Day 63 of follow-up. Subjects were
followed for an additional month (to Day 90). This
period of follow-up allowed us to capture essentially all
early relapses that would occur under normal circum-
stances (within 63 days), as well as assess if tinidazole
delayed but did not fully eliminate recurrence. Subjects
without a recurrence at 90 days were considered to haveachieved radical cure. Day 0 was defined as the first day
a patient received a study drug. Subjects that presented
with concomitant P. falciparum infection or were other-
wise unable to complete the study were replaced with a
new subject.Statistical analysis and assessment of efficacy
This study utilized a form of sequential analysis known
as a modified triangular test in order to evaluate
tinidazole efficacy in the prevention of P. vivax relapse.
This method allows for repeated analysis as each subject
reaches a study endpoint while maintaining a pre-
specified α and β error. It allows enrolment to be
stopped when there is information sufficient to reach a
conclusion available from subjects that have already
reached a study endpoint, but it requires the tested drug
to demonstrate a substantial benefit to be considered
successful. The study used straight line stopping bound-
aries with a closed continuation region. This means that
while the number of total subjects needed was partially
based on results as each subject reaches either the pri-
mary or secondary endpoint (cure at 63 days or relapse),
the number of potential subjects was limited to 50 at
which point one of the boundaries would have to be
crossed. The mathematical basis for this technique has
been explained in detail elsewhere [6,18,19].
In order to apply the modified triangular sequential
analysis technique used in this study it is necessary to
make a determination of thresholds for success and fail-
ure, to create statistical boundaries and then evaluate,
via a pre-calculated formula after each subject reaches
an endpoint, whether the success or failure threshold or
boundary has been crossed or not.
Applied to this study, the key statistical end point is
the proportion of subjects that did not have relapsing
disease within the trial period. The goal was to deter-
mine whether that proportion is higher than the preset
threshold value. That threshold is the largest response
rate (absence of relapse) for which further investigation
of tinidazole would be not worthwhile. In other words, it
represents the point just beyond the maximum amount
of failure that could be tolerated in order to suspend
drawing a conclusion. Therefore, the null hypothesis is
described as H0: ρ > = ρ0, where ρ0 represents the
threshold value pre-determined beyond which tinidazole
would be considered a failure and ρ represents the pro-
portion actually observed in the study. Since the thresh-
old value was pre-determined, the alternative hypothesis
Ha, was ρ < ρa where ρa represented the smallest re-
sponse rate (no relapse) for which further investigations
would be worthwhile. This can also be described as the
smallest amount of success that was needed to warrant
further investigation of tinidazole.
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error and a 90% power (α = 0.05 and β = 0.10). A relapse
rate of <20% indicated an adequate response and thus
the minimum improvement in relapse rate necessary to
warrant further study at the β = 0.10 level, while a re-
lapse rate > =45% indicated insufficient protection and
response. Utilizing the description above, the ρ0 = 0.45
and the ρa = 0.20. With the use of these pre-determined
parameters, the boundaries of the triangular test with
specific Z and V statistics were determined based on the
accumulation of data that precedes each discrete evalu-
ation. Z is representative of the results to date prior to
each calculation and V is representative of how many
subjects had reached an endpoint at the time of each
calculation.
The following information, based on the preset values
was programmed into “R Version 2.7.2, 2008”, a free
open-source statistical program created by the R Foun-
dation for Statistical Computing (ISBN 3-900051-07-0)
accessible from the R Project for Statistical Computing
[20] as follows:
p0 < − 0.45
p1 < − 0.20
alpha < − 0.05
beta < − 0.10
Theta < − log ((p1* (1-p0))/(p0* (1-p1)))
A1 < − 2/Theta*log(1/(2*alpha))
A = A1-0.583*sqrt(p0*(1-p0))
Theta = Theta*(2*qnorm(1-alpha)/(qnorm(1-alpha) +
qnorm(1-beta)))
Lamda = Theta1/4Figure 1 legend text: Graphical representation of assessed Z and V sc
each subject reached an endpoint of recurrence prior to 63 days or non-re
represent the third and seventh subject’s endpoint evaluation. Evaluation o
halted. Values after that point represent subjects already enrolled when enAs a result, the boundary lines for this investigation
(demonstrated graphically with linear lines on a V versus
Z graph) are represented by the formulas:
Lower boundary (values below which demonstrate
significant improvement) Z = −4.17-0.33V
Upper boundary (values above which demonstrate no
significant improvement) Z = 4.17-0.99V
During each analysis (each time a subject reached an
endpoint), the Z and V values were determined by:
Z = S – N(p0)
V = N(p0)(1-p0)
Where p0 = 0.45
S = number of recurrences observed to that point and
N = the number of subjects included
In this investigation, an analysis was done after each
subject either had a recurrence or reached Day 63 with-
out a recurrence. With each analysis, a “V” and “Z” value
(the x and y axes on a graphical plot in Figure 1) was
calculated as well as the applicable limits of the test for
that analysis (the boundary lines on a graphical plot). If
the calculated “Z” value was above or below the Z value
boundary line value, the study would be halted and the
applicable conclusion made. If the calculated “Z” value
was between the boundary values (within the triangular
lines on the graphical plot), enrolment would continue
unless 50 subjects had already reached the primary study
endpoints of success at 63 Days (no recurrence) or
failure (recurrence or co-infection) at which time theores and corresponding boundaries. An evaluation was made after
currence at 63 days. Highlighted Z score values of 0.65 and 2.85
f the seventh subject crossed the failure threshold and enrolment was
rolment was terminated.
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of these values was pre-calculated for every possible per-
mutation of results, they are best understood and illus-
trated by a graphical representation (See Figure 1) which
also contains a partial listing of representative calculated
values.
Assessment of safety
A medical history and physical exam was performed at
the time of screening. CBC (Complete blood count),
ALT (alanine aminotransferase), GGT (gamma-glutamyl
transpeptidase), BUN (Blood urea nitrogen), creati-
nine, glucose-6-phosphate-dehydrogenase (G6PD) levels,
HRP-2 (Histidine-rich protein-2 specific to P. falciparum
infection) and two thick/thin peripheral malaria blood
smear slides were done to confirm diagnosis of P. vivax
malaria mono-infection, and to quantify parasitaemia.
Female subjects also submitted urine for a human beta
chorionic gonadotropin (βHCG) test for pregnancy. The
results of the screening history/physical and laboratory
assessments were reviewed for any significant abnormal-
ity. Serum chemistries and complete blood counts were
also done on Day 3 prior to the fourth dose of study
drug and on Day 14. Subjects were monitored for ad-
verse events and questioned about symptoms known to
occur with use of the study drugs as well as for any
other symptoms at each follow-up visit. While only
those subjects reaching the primary endpoint of cure or
the secondary endpoint of relapse were considered for
efficacy analysis, all subjects enrolled receiving at least
one dose of the study drug were included in all safety
analyses.
Results
20 active subjects were enrolled by the time the study
crossed its statistical boundary of failure, 14 to the treat-
ment arm and six to the positive comparator arm. In the
treatment arm, 11 subjects had a recurrence of P. vivax
within 63 Days and three subjects achieved cure of both
liver and blood stages without relapse at day 90 (radical
cure). Enrolment was halted when the 6th of the first
seven subjects to reach an endpoint had a recurrence
(Figure 1). In the positive comparator arm, all six sub-
jects achieved radical cure and none were re-infected
during the course of the study. Ten of the 11 failures in
the treatment arm had an apparent mild delay in relapse
with a mean of 47 days compared to the historical time
to recurrence discussed above of approximately four
weeks. While tinidazole may have prolonged the average
time to relapse and resulted in occasional radical cure, it
did not meet the pre-determined study threshold for
success.
Three additionally enrolled subjects had to be re-
placed. One subject withdrew consent due to vomitingand difficulty swallowing pills. Another subject was
removed from the study due to a mild elevation of his
liver enzymes and slight jaundice and a third relocated
from the region and was lost to follow-up. The drug
combination was well tolerated. Adverse events were
mild and mostly consisted of gastrointestinal complaints
and headache.
Discussion
The use of tinidazole in this study had the potential ad-
vantage of being a drug that is already approved for use
in extra-intestinal amoebiasis in combination with
chloroquine in the dose used in this trial. It also had the
advantage of representing the possibility of a shorter
dosing regimen than is the standard of care for achieving
radical cure of P. vivax and without the potential of
causing haemolysis. Unfortunately, tinidazole was unsuc-
cessful in achieving radical cure with the dosing regimen
used. However, several notable observations as a result
of this study can be made.
The modest liver stage activity in P. vivax parallels re-
sults of the macaque/P. cynomolgi model with one of six
cured and five of six achieving a mild delay in relapse
with tinidazole, lending support to the use of the ma-
caque/P. cynomolgi model in the evaluation of potential
liver stage candidate drugs. Additionally, this study dem-
onstrates the usefulness of a modified triangular test se-
quential analysis technique in limiting enrolment to a
failing regimen, limiting exposure of the study popula-
tion to the study drug and limiting expenditure with re-
spect to products that have enough potential to warrant
human study, but do not compel immediate full-scale
investigation in a human model. This saves time, energy
and resources that can be applied to other promising
candidate drugs while at the same time not abandoning
potential candidates prematurely that can only be truly
studied in a human model.
Conclusions
Tinidazole at 2 gms daily for 5 days given concurrently
with chloroquine may show modest liver stage activity,
but is ineffective in preventing the relapse of P.vivax
malaria. The macaque relapsing model appears to accur-
ately predict outcome for 5-nitroimidazoles in humans
with symptomatic P. vivax. Use of the modified triangu-
lar test analysis allowed limited enrolment to a failing
regimen adding weight to the ethical and economical ad-
vantages of this technique when appropriate.
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